Garmpis N, Damaskos C, Garmpi A, Spartalis E, Kalampokas E, Kalampokas T, Margonis GA, Schizas D, Andreatos N, Angelou A, Lavaris A, Athanasiou A, Apostolou KG, Spartalis M, Damaskou Z, Daskalopoulou A, Diamantis E, Tsivelekas K, Alavanos A, Valsami S, Moschos MM, Sampani A, Nonni A, Antoniou EA, Mantas D, Tsourouflis G, Markatos K, Kontzoglou K, Perrea D, Nikiteas N, Kostakis A, Dimitroulis D. Targeting histone deacetylases in endometrial cancer: a paradigm-shifting therapeutic strategy?
Eur Rev Med Pharmacol Sci 2019;
22:950-960. [PMID:
29509243 DOI:
10.26355/eurrev_201802_14376]
[Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Abstract
OBJECTIVE
Endometrial cancer is increasingly prevalent in western societies and affects mainly postmenopausal women; notably incidence rates have been rising by 1.9% per year on average since 2005. Although the early-stage endometrial cancer can be effectively managed with surgery, more advanced stages of the disease require multimodality treatment with varying results. In recent years, endometrial cancer has been extensively studied at the molecular level in an attempt to develop effective therapies. Recently, a family of compounds that alter epigenetic expression, namely histone deacetylase inhibitors, have shown promise as possible therapeutic agents in endometrial cancer. The present review aims to discuss the therapeutic potential of these agents.
MATERIALS AND METHODS
This literature review was performed using the MEDLINE database; the search terms histone, deacetylase, inhibitors, endometrial, targeted therapies for endometrial cancer were employed to identify relevant studies. We only reviewed English language publications and also considered studies that were not entirely focused on endometrial cancer. Ultimately, sixty-four articles published until January 2018 were incorporated into our review.
RESULTS
Studies in cell cultures have demonstrated that histone deacetylase inhibitors exert their antineoplastic activity by promoting expression of p21WAF1 and p27KIP1, cyclin-dependent kinase inhibitors, that have important roles in cell cycle regulation; importantly, the transcription of specific genes (e.g., E-cadherin, PTEN) that are commonly silenced in endometrial cancer is also enhanced. In addition to these abstracts effects, novel compounds with histone deacetylase inhibitor activity (e.g., scriptaid, trichostatin, entinostat) have also demonstrated significant antineoplastic activity both in vitro and in vivo, by liming tumor growth, inducing apoptosis, inhibiting angiogenesis and potentiating the effects of chemotherapy.
CONCLUSIONS
The applications of histone deacetylase inhibitors in endometrial cancer appear promising; nonetheless, additional trials are necessary to establish the therapeutic role, clinical utility, and safety of these promising compounds.
Collapse